Bioventus 2026 shareholder meeting voting results

Bioventus Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Bioventus Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. A total of 75,279,174 shares of Class A and Class B common stock were present in person or by proxy, representing approximately 90.23% of outstanding shares entitled to vote as of the April 6, 2026 record date.

Stockholders elected all nominated directors to the Board to serve until the 2027 annual meeting and until their successors are elected and qualified, or earlier death, resignation or removal. The filing lists individual vote totals and broker non-votes for each director.

Stockholders also ratified the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,228,481 shares voting for, 5,021 against and 45,672 abstaining, and no broker non-votes reported on this item.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares represented at meeting: 75,279,174 shares Quorum percentage: 90.23% Votes for Ajay Dhankhar: 68,459,149 shares +4 more

7 metrics

Shares represented at meeting 75,279,174 shares Class A and Class B common stock present or by proxy at 2026 Annual Meeting

Quorum percentage 90.23% Portion of outstanding shares entitled to vote as of April 6, 2026 record date

Votes for Ajay Dhankhar 68,459,149 shares Votes cast “For” election of director nominee Ajay Dhankhar

Votes for Martin P. Sutter 61,710,650 shares Votes cast “For” election of director nominee Martin P. Sutter

Auditor ratification votes for 75,228,481 shares Votes “For” ratifying Grant Thornton LLP as independent registered public accounting firm

Auditor ratification votes against 5,021 shares Votes “Against” ratifying Grant Thornton LLP as independent registered public accounting firm

Auditor ratification abstentions 45,672 shares Shares abstaining on ratification of Grant Thornton LLP

Key Terms

Annual Meeting of Stockholders, broker non-votes, independent registered public accounting firm, record date, +1 more

5 terms

Annual Meeting of Stockholders financial

"Bioventus, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 3, 2026."

broker non-votes financial

"At the 2026 Annual Meeting, the stockholders elected the following directors ... based on the following votes ... Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"The stockholders also ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

record date financial

"representing approximately 90.23% of the outstanding Shares of Common Stock entitled to vote as a single class as of the April 6, 2026 record date."

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

abstaining financial

"The vote for such ratification was 75,228,481 Shares for, 5,021 Shares against, 45,672 Shares abstaining, and no broker non-votes."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bioventus (BVS) report in its 2026 Annual Meeting results?

Bioventus reported voting results from its 2026 Annual Meeting. Shareholders elected all nominated directors and ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, based on the detailed vote counts disclosed.

How many Bioventus shares were represented at the 2026 Annual Meeting?

A total of 75,279,174 shares of Bioventus Class A and Class B common stock were represented. This represented approximately 90.23% of the outstanding shares entitled to vote as of the April 6, 2026 record date, indicating a high level of shareholder participation.

Were all Bioventus director nominees elected at the 2026 Annual Meeting?

Yes, all listed Bioventus director nominees were elected. Each nominee received more votes “For” than “Withheld,” with individual results reported, and will serve until the 2027 annual meeting and until a successor is elected and qualified or earlier death, resignation or removal.

Who is Bioventus’s independent auditor for the year ending December 31, 2026?

Shareholders ratified Grant Thornton LLP as Bioventus’s independent registered public accounting firm for the year ending December 31, 2026. The ratification received 75,228,481 votes for, 5,021 votes against and 45,672 abstentions, with no broker non-votes reported on this proposal.

What was the quorum percentage at Bioventus’s 2026 Annual Meeting of Stockholders?

The quorum at Bioventus’s 2026 Annual Meeting was approximately 90.23% of outstanding shares. This percentage reflects the portion of Class A and Class B common stock present in person or represented by proxy and entitled to vote as of the April 6, 2026 record date.

Which Bioventus director nominee received the lowest number of votes for election?

Among the disclosed Bioventus director nominees, Martin P. Sutter received the lowest number of votes for election, with 61,710,650 votes “For,” 6,824,305 votes “Withheld,” and 6,744,219 broker non-votes recorded in the voting results table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/04/2026 - 07:54 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

Bioventus Inc.

(Exact name of registrant as specified in charter)

Delaware

001-37844

81-0980861

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

4721 Emperor Boulevard, Suite 100

Durham, North Carolina 27703

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (919) 474-6700

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Class A common Stock, $0.001 par value per share

BVS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.07. Submission of Matters to a Vote of Security Holders.

Bioventus, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 3, 2026. A total of 75,279,174 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, the “Common Stock”) were present in person or represented by proxy at the 2026 Annual Meeting, representing approximately 90.23% of the outstanding Shares of Common Stock entitled to vote as a single class as of the April 6, 2026 record date.

The following proposals were voted upon at the 2026 Annual Meeting and the final voting results with respect to each such proposal are set forth below.

At the 2026 Annual Meeting, the stockholders elected the following directors to serve on the Company’s Board of Directors until the 2027 annual meeting of stockholders and until each such director’s respective successor is elected and qualified, or until each such director’s death, resignation or removal, based on the following votes:


Nominee	For	Withheld	Broker Non-Votes
William A. Hawkins	67,405,961	1,128,994	6,744,219
John A. Bartholdson	68,365,980	168,975	6,744,219
Patrick J. Beyer	68,062,114	472,841	6,744,219
Robert E. Claypoole	68,360,467	174,488	6,744,219
Philip G. Cowdy	67,748,512	786,443	6,744,219
Ajay Dhankhar	68,459,149	75,806	6,744,219
Mary Kay Ladone	67,160,936	1,374,019	6,744,219
Michelle McMurry-Heath	68,073,685	461,270	6,744,219
Guido J. Neels	68,049,659	485,296	6,744,219
Guy P. Nohra	67,767,651	767,304	6,744,219
Susan M. Stalnecker	68,060,987	473,968	6,744,219
Martin P. Sutter	61,710,650	6,824,305	6,744,219

The stockholders also ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 75,228,481 Shares for, 5,021 Shares against, 45,672 Shares abstaining, and no broker non-votes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	BIOVENTUS INC.

Date: June 4, 2026	By:	/s/ Anthony D’Adamio
		Anthony D’Adamio Senior Vice President and General Counsel

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents